S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
S&P 500   4,443.11
DOW   34,869.37
QQQ   370.35
NASDAQ:RDHL

RedHill Biopharma News Headlines

$5.14
+0.15 (+3.01 %)
(As of 09/27/2021 04:00 PM ET)
Add
Compare
Today's Range
$4.93
$5.15
50-Day Range
$4.55
$10.36
52-Week Range
$4.48
$11.52
Volume1.05 million shs
Average Volume564,898 shs
Market Capitalization$239.87 million
P/E RatioN/A
Dividend YieldN/A
Beta1.47

Media Mentions By Week

RedHill Biopharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RDHL
News Sentiment

0.13

0.35

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RDHL Articles
This Week

7

3

RDHL Articles
Average Week

Get RedHill Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

RedHill Biopharma (NASDAQ RDHL) News Headlines Today

SourceHeadline
MarketBeat logoRedHill Biopharma Ltd. (NASDAQ:RDHL) Expected to Announce Quarterly Sales of $23.41 Million
americanbankingnews.com - September 25 at 2:18 AM
MarketBeat logoHC Wainwright Reaffirms "Buy" Rating for RedHill Biopharma (NASDAQ:RDHL)
americanbankingnews.com - September 24 at 8:48 AM
MarketBeat logoRedHill Biopharma Ltd. (NASDAQ:RDHL) Expected to Post Earnings of -$0.48 Per Share
americanbankingnews.com - September 23 at 5:20 PM
nasdaq.com logoRedHill Biopharma Announces Movantik Patent Litigation Settlement With Aurobindo
nasdaq.com - September 23 at 8:50 AM
nasdaq.com logoRedHill Biopharma Says Resolves Movantik Patent Litigation With Aurobindo
nasdaq.com - September 23 at 8:50 AM
finance.yahoo.com logoRedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo
finance.yahoo.com - September 23 at 8:50 AM
nasdaq.com logoRedhill Biopharma - ADR Shares Close the Week 45.6% Lower - Weekly Wrap
nasdaq.com - September 17 at 10:44 PM
finance.yahoo.com logoRedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study
finance.yahoo.com - September 15 at 1:26 PM
MarketBeat logoRedHill Biopharma (NASDAQ:RDHL) Price Target Cut to $16.00
americanbankingnews.com - September 15 at 8:38 AM
finance.yahoo.com logoWhy RedHill Biopharma Stock Is Getting Crushed Today
finance.yahoo.com - September 14 at 5:22 PM
MarketBeat logoRedHill Biopharma (NASDAQ:RDHL) Given "Buy" Rating at HC Wainwright
americanbankingnews.com - September 14 at 1:04 PM
markets.businessinsider.com logoRedHill Biopharma: Opaganib Fails To Meet Primary Endpoint In Phase 2/3 Study
markets.businessinsider.com - September 14 at 8:52 AM
finance.yahoo.com logoRedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients
finance.yahoo.com - September 14 at 8:52 AM
finance.yahoo.com logoRedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval
finance.yahoo.com - September 13 at 8:10 AM
finance.yahoo.com logoRHB-107 P2/3 COVID-19 Study South Africa Approval
finance.yahoo.com - September 13 at 8:10 AM
finance.yahoo.com logoRedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis
finance.yahoo.com - September 8 at 4:57 PM
proactiveinvestors.com logoRedHill Biopharma notes study demonstrates opaganib's efficacy in significantly decreasing renal fibrosis
proactiveinvestors.com - September 8 at 8:36 AM
finance.yahoo.com logoRedHill Unveils New Movantik Data For Opioid-Induced Constipation
finance.yahoo.com - September 7 at 5:35 PM
finanznachrichten.de logoRedHill Biopharma Ltd.: RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
finanznachrichten.de - September 7 at 8:04 AM
finanznachrichten.de logoRedHill Biopharma Ltd.: RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
finanznachrichten.de - September 7 at 8:04 AM
finance.yahoo.com logoRedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
finance.yahoo.com - September 7 at 8:04 AM
finance.yahoo.com logoRedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021
finance.yahoo.com - September 7 at 8:04 AM
finance.yahoo.com logoRedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek
finance.yahoo.com - September 7 at 8:04 AM
finance.yahoo.com logoRedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis
finance.yahoo.com - September 7 at 8:04 AM
MarketBeat logoRedHill Biopharma Ltd. (NASDAQ:RDHL) Receives Consensus Rating of "Buy" from Brokerages
americanbankingnews.com - September 5 at 3:46 AM
MarketBeat logoZacks: Brokerages Expect RedHill Biopharma Ltd. (NASDAQ:RDHL) Will Post Earnings of -$0.48 Per Share
americanbankingnews.com - September 4 at 5:22 PM
finanznachrichten.de logoRedHill Biopharma Ltd: RedHill to Present at HCW & Cantor Conferences
finanznachrichten.de - September 3 at 10:34 PM
finance.yahoo.com logoRedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences
finance.yahoo.com - September 2 at 5:12 PM
finance.yahoo.com logoRedHill to Present at HCW & Cantor Conferences
finance.yahoo.com - September 2 at 5:12 PM
finance.yahoo.com logoWhy RedHill Biopharma Stock Jumped on Tuesday
finance.yahoo.com - August 31 at 5:12 PM
nasdaq.com logoRedHill Biopharma: Opaganib Shows Strong Inhibition Of COVID-19 Delta Variant
nasdaq.com - August 28 at 5:11 PM
proactiveinvestors.com logoRedHill Biopharma shows strong inhibition by opaganib of the coronavirus Delta variant
proactiveinvestors.com - August 27 at 3:22 PM
finanznachrichten.de logoRedHill Biopharma Ltd.: RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
finanznachrichten.de - August 26 at 1:36 PM
proactiveinvestors.com logoRedHill Biopharma demonstrates strong inhibition by opaganib of the coronavirus (COVID-19) Delta variant
proactiveinvestors.com - August 26 at 1:36 PM
msn.com logoThe Daily Biotech Pulse: Early Approval For Ascendis' Pediatric Growth Hormone Deficiency Treatment, Redhill Biopharma Spikes On Positive COVID-19 Drug Data, RenovoRx IPO
msn.com - August 26 at 1:36 PM
baystreet.ca logoRed Hill Shares Hike as COVID Candidate Shows Promise
baystreet.ca - August 26 at 1:36 PM
benzinga.com logoRedhill Biopharma: Q2 Earnings Insights
benzinga.com - August 26 at 1:36 PM
finance.yahoo.com logoRedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant
finance.yahoo.com - August 26 at 1:36 PM
finance.yahoo.com logoRedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant
finance.yahoo.com - August 26 at 6:38 AM
proactiveinvestors.com logoRedHill Biopharma says USPTO has issued it with two new patents for opaganib for Ebola Virus and RHB-104 for Crohn’s
proactiveinvestors.com - August 23 at 4:17 PM
finance.yahoo.com logoRedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
finance.yahoo.com - August 23 at 8:56 AM
finance.yahoo.com logoRedHill Announces Two New U.S. Patents
finance.yahoo.com - August 23 at 8:56 AM
finance.yahoo.com logoRedHill Biopharma to Host Second Quarter 2021 Financial Results and Operational Highlights Webcast on August 26, 2021
finance.yahoo.com - August 19 at 8:14 AM
finanznachrichten.de logoRedHill Biopharma Ltd: RedHill Settles Movantik Apotex Patent Litigation
finanznachrichten.de - July 24 at 7:16 PM
finance.yahoo.com logoRedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Apotex
finance.yahoo.com - July 22 at 2:05 PM
finance.yahoo.com logoRedHill Settles Movantik(R) Apotex Patent Litigation
finance.yahoo.com - July 22 at 2:05 PM
finance.yahoo.com logoRedHill Biopharma Significantly Extends Unrestricted Commercial Coverage for Talicia® with OptumRx
finance.yahoo.com - July 20 at 8:31 AM
finance.yahoo.com logoRedHill Extends Talicia Commercial Coverage
finance.yahoo.com - July 20 at 8:31 AM
finanznachrichten.de logoRedHill Biopharma Ltd: RedHill Biopharma Announces Last Patient Out
finanznachrichten.de - July 19 at 1:55 PM
proactiveinvestors.com logoRedHill Biopharma completes treatment and follow-up in the 475-patient global Phase 2/3 COVID-19 study with opaganib
proactiveinvestors.com - July 19 at 1:55 PM
Get RedHill Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for RDHL and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/28/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.